KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Debt to Equity: 2019-2025

Historic Debt to Equity for Royalty Pharma (RPRX) over the last 6 years, with Sep 2025 value amounting to $0.93.

  • Royalty Pharma's Debt to Equity rose 25.39% to $0.93 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.93, marking a year-over-year increase of 25.39%. This contributed to the annual value of $0.74 for FY2024, which is 20.98% up from last year.
  • According to the latest figures from Q3 2025, Royalty Pharma's Debt to Equity is $0.93, which was up 10.42% from $0.84 recorded in Q2 2025.
  • Royalty Pharma's Debt to Equity's 5-year high stood at $0.93 during Q3 2025, with a 5-year trough of $0.57 in Q2 2021.
  • Over the past 3 years, Royalty Pharma's median Debt to Equity value was $0.74 (recorded in 2024), while the average stood at $0.74.
  • As far as peak fluctuations go, Royalty Pharma's Debt to Equity declined by 18.56% in 2023, and later rose by 25.39% in 2025.
  • Over the past 5 years, Royalty Pharma's Debt to Equity (Quarterly) stood at $0.70 in 2021, then climbed by 6.28% to $0.75 in 2022, then dropped by 18.56% to $0.61 in 2023, then climbed by 20.98% to $0.74 in 2024, then increased by 25.39% to $0.93 in 2025.
  • Its last three reported values are $0.93 in Q3 2025, $0.84 for Q2 2025, and $0.78 during Q1 2025.